Vext Science, Inc. Q1 2026 Earnings Recap

Vext’s shares climbed modestly by 1.7% following its Q1 2026 earnings, reflecting a largely steady performance with improving profitability driven by Ohio operations offsetting ongoing headwinds in Arizona. The market reaction signals cautious approval but not enthusiasm, likely reflecting mixed contributions across regions and an ongoing margin focus.

Key Takeaways

• Revenue rose 5% year-over-year to $12.2 million, led by a 34% increase in Ohio to $8.2 million, supported by new dispensaries and improved cultivation.
• Arizona revenue declined 24%, weighed down by oversupplied wholesale market and pricing pressure, with wholesale revenue down roughly 50% year-over-year.
• Gross profit more than doubled to $5.5 million, with a positive margin shift to 45.4%, driven by operating leverage and retail mix improvements in Ohio.
• Adjusted EBITDA increased to $3.6 million, or 29.3% margin, up from 15% last year, reflecting better profitability despite ongoing drag from Arizona.
• Cash from operations was $1.6 million despite temporary working capital challenges, with continued focus on Ohio expansion and planned completion of Arizona cultivation exit by end Q2.